Accessibility helpSkip to navigationSkip to contentSkip to footer

Cookies on FT Sites

We use cookies and other data for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.

Accept cookies
Manage cookies
  • Sign In
  • Subscribe
Open side navigation menuOpen search bar
Financial Times
SubscribeSign InmyFT
  • Home
  • World
    Sections
    • World Home
    • Global Economy
    • UK
    • US
    • China
    • Africa
    • Asia Pacific
    • Emerging Markets
    • Europe
    • War in Ukraine
    • Americas
    • Middle East & North Africa
    • Australia & NZ
    Most Read
    • Benjamin Netanyahu delays judicial reforms after day of turmoil
    • China grants billions in bailouts as Belt and Road Initiative falters
    • Generative AI set to affect 300mn jobs across major economies
    • Pay transparency laws in US stir worker discontent
    • Top Fed official blasts SVB collapse as ‘textbook case of mismanagement’
  • US
    Sections
    • US Home
    • US Economy
    • US Companies
    • US Politics & Policy
    Most Read
    • Companies
      Sections
      • Companies Home
      • Banks in turmoil
      • Energy
      • Financials
      • Health
      • Industrials
      • Media
      • Professional Services
      • Retail & Consumer
      • Tech Sector
      • Telecoms
      • Transport
      Most Read
      • Saudi National Bank chair resigns following Credit Suisse comments
      • European ammunition maker says plant expansion hit by energy-guzzling TikTok site
      • First Citizens shares surge after Silicon Valley Bank deal
      • Tesla cars lose value faster than rival models after price cuts, data shows
      • Air India boss hails biggest turnround effort in airline’s history
    • Tech
    • Markets
      Sections
      • Markets Home
      • Alphaville
      • Markets Data
      • Cryptofinance
      • Capital Markets
      • Commodities
      • Currencies
      • Equities
      • Fund Management
      • Trading
      • Moral Money
      • ETF Hub
      Most Read
      • Live news updates from March 27: Netanyahu delays judicial overhaul, First Citizens buys much of SVB
      • Top Fed official blasts SVB collapse as ‘textbook case of mismanagement’
      • Money market funds swell by more than $286bn amid deposit flight
      • Live news: Alibaba to split into 6 independent units
      • Crypto exchange Binance accused by CFTC of illegally serving US clients
    • Climate
    • Opinion
      Sections
      • Opinion Home
      • Columnists
      • The FT View
      • Lex
      • Obituaries
      • Letters
      Most Read
      • A new technology boom is at hand
      • China, Japan and the Ukraine war
      • Final salary pensions have been uniquely horrible for UK plc
      • We are all secretaries now
      • Why five days in the office don’t add up
    • Work & Careers
      Sections
      • Work & Careers Home
      • Business School Rankings
      • Business Education
      • Entrepreneurship
      • Recruitment
      • Business Books
      • Business Travel
      Most Read
      • Matthew Desmond: ‘America does so much more to subsidise affluence than alleviate poverty’
      • Culture clash: the challenge of uniting fierce rivals UBS and Credit Suisse
    • Life & Arts
      Sections
      • Life & Arts Home
      • Arts
      • Books
      • Food & Drink
      • FT Magazine
      • House & Home
      • Style
      • Travel
      • FT Globetrotter
      Most Read
      • Everything I, an Italian, thought I knew about Italian food is wrong
      • My life with Ozempic – a weight-loss diary
      • The best black watches
      • Is France on the road to a Sixth Republic?
      • At LVMH, the legendary Gérald Genta brand is born again
    • HTSI
    MenuSearch
    • Home
    • World
    • US
    • Companies
    • Tech
    • Markets
    • Climate
    • Opinion
    • Work & Careers
    • Life & Arts
    • HTSI
    Financial Times
    SubscribeSign In

    Illumina Inc

    Add to myFT Digest

    Add this topic to your myFT Digest for news straight to your inbox

    • Friday, 24 March, 2023
      Carl Icahn says Illumina directors demanded extra insurance for Grail deal

      Activist investor steps up battle over ‘disastrous’ acquisition by world’s biggest genome sequencer

    • Friday, 17 March, 2023
      InterviewCarl Icahn
      Carl Icahn urges Fed to keep fighting inflation ‘disease’

      Comments by activist investor come ahead of US central bank’s rate-setting meeting next week

    • Monday, 13 March, 2023
      Carl Icahn takes aim at genome sequencer Illumina over Grail deal

      Company’s shares jump after activist investor launches proxy battle

    • Tuesday, 7 February, 2023
      Health sector
      Illumina boosts spending on US lobbying amid opposition to Grail acquisition

      Genome sequencing company paid firms $14.6mn over past two years to try to sway lawmakers

    • Sunday, 29 January, 2023
      News in-depth
      Has Illumina taken the wrong path in its Grail quest?

      DNA sequencing expert’s investors question acquisition of cancer testing group that has also angered EU regulators

    • Monday, 5 September, 2022
      Illumina to challenge Brussels over any block on Grail merger

      US biotech to object to impending EU ruling on $8bn deal for cancer screening group

    • Thursday, 1 September, 2022
      Illumina wins battle against US regulators trying to block $8bn Grail deal

      Setback for FTC after administrative law judge gives nod to acquisition of cancer testing group

    • Wednesday, 13 July, 2022
      EU business regulation
      EU court ruling expands Brussels’ powers to scrutinise tech mergers

      Ruling allows European probe of Illumina’s $8bn Grail takeover and sets precedent for deeper oversight of deals

    • Sunday, 16 January, 2022
      Illumina says EU probe of $8bn Grail deal could hit biotech investment

      Chief executive deSouza attacks regulatory intervention over cancer test company

    • Wednesday, 18 August, 2021
      Illumina pushes ahead with closing $8bn Grail merger in defiance of EU probe

      US biotech takes aggressive step over cancer-screening deal fearing Brussels review will not beat deadline

    • Wednesday, 14 July, 2021
      Brooke Masters
      Competition enforcement is harder than it looks

      Novel antitrust cases complicate efforts to tackle climate change and healthcare

    • Tuesday, 1 June, 2021
      Illumina accuses US regulators of time-wasting over $8bn Grail deal

      Biotech group’s chief warns lives will be at risk if approval process is delayed

    • Thursday, 29 April, 2021
      Illumina sues Brussels over probe into $8bn cancer deal for Grail

      US genomics company takes rare step after authorities indicate they will review the deal

    • Wednesday, 31 March, 2021
      Lex
      Illumina: vertical acquisition in the crosshairs Premium content

      Competition regulator’s move on Grail purchase confirms era of bolder antitrust bodies

    • Tuesday, 23 February, 2021
      Genomics
      Genomic sequencing head calls for ‘Bio Force’ to detect virus threats

      Illumina’s Francis De Souza says global co-operation needed to keep up with new strains

    • Monday, 21 September, 2020
      Biotech
      Illumina agrees $8bn deal for cancer screening group Grail

      Genetic sequencing company set to take full ownership of start-up

    • Friday, 3 January, 2020
      Pharmaceuticals sector
      Illumina and Pacific Biosciences call off merger

      Mooted $1.2bn deal halted after scrutiny by UK and US competition watchdogs

    • Monday, 30 July, 2018
      Technology sector
      Illumina shares lit up by earnings beat, outlook raise
    • Tuesday, 1 August, 2017
      Corporate earnings and results
      Illumina rises as its boosts forecast, posts earnings beat
    • Thursday, 10 November, 2016
      LexEuropean companies
      Siemens: healthy cynicism

      Separating the healthcare unit makes sense. Announcing it now does not

    • Tuesday, 11 October, 2016
      World
      Healthcare clocks sharpest decline in broad S&P 500 sell-off
    • Tuesday, 11 October, 2016
      US equities
      Illumina shares slide on sales ‘credibility gap’

      US stocks retreat as healthcare sector posts heaviest losses

    • Tuesday, 11 October, 2016
      US equities
      S&P falls 1% as US stocks extend declines
    • Monday, 10 October, 2016
      Companies
      Illumina tumbles 25% after sales warning
    • Thursday, 2 June, 2016
      Pharmaceuticals sector
      President raises patient and business hope for cancer treatment

      Many experts believe a new type of drug promises to revolutionise treatment

    Previous page You are on page 1 Next page

    Useful links

    Support

    View Site TipsHelp CentreContact UsAbout UsAccessibilitymyFT TourCareers

    Legal & Privacy

    Terms & ConditionsPrivacy PolicyCookiesCopyrightSlavery Statement & Policies

    Services

    Share News Tips SecurelyIndividual SubscriptionsGroup SubscriptionsRepublishingExecutive Job SearchAdvertise with the FTFollow the FT on TwitterFT ChannelsSecondary Schools

    Tools

    PortfolioToday's Newspaper (ePaper)Alerts HubBusiness School RankingsEnterprise ToolsNews feedNewslettersCurrency Converter

    Community & Events

    FT CommunityFT Live EventsFT ForumsFT Board DirectorBoard Director Programme

    More from the FT Group

    Markets data delayed by at least 15 minutes. © THE FINANCIAL TIMES LTD 2023. FT and ‘Financial Times’ are trademarks of The Financial Times Ltd.
    The Financial Times and its journalism are subject to a self-regulation regime under the FT Editorial Code of Practice.
    Financial Times

    International Edition

    Subscribe for full access
    • Switch to UK Edition

    Top sections

    • Home
    • World
      • Global Economy
      • UK
      • US
      • China
      • Africa
      • Asia Pacific
      • Emerging Markets
      • Europe
      • War in Ukraine
      • Americas
      • Middle East & North Africa
      • Australia & NZ
    • US
      • US Economy
      • US Companies
      • US Politics & Policy
    • Companies
      • Banks in turmoil
      • Energy
      • Financials
      • Health
      • Industrials
      • Media
      • Professional Services
      • Retail & Consumer
      • Tech Sector
      • Telecoms
      • Transport
    • Tech
    • Markets
      • Alphaville
      • Markets Data
      • Cryptofinance
      • Capital Markets
      • Commodities
      • Currencies
      • Equities
      • Fund Management
      • Trading
      • Moral Money
      • ETF Hub
    • Climate
    • Opinion
      • Columnists
      • The FT View
      • Lex
      • Obituaries
      • Letters
    • Work & Careers
      • Business School Rankings
      • Business Education
      • Entrepreneurship
      • Recruitment
      • Business Books
      • Business Travel
    • Life & Arts
      • Arts
      • Books
      • Food & Drink
      • FT Magazine
      • House & Home
      • Style
      • Travel
      • FT Globetrotter
    • Personal Finance
      • Property & Mortgages
      • Investments
      • Pensions
      • Tax
      • Banking & Savings
      • Advice & Comment
      • Next Act
    • HTSI
    • Special Reports

    FT recommends

    • Lex
    • Alphaville
    • Lunch with the FT
    • FT Globetrotter
    • #techAsia
    • Moral Money
    • FTfm
    • Newsletters
    • Video
    • Podcasts
    • News feed
    • FT Live Events
    • FT Forums
    • Board Director Programme
    • myFT
    • Portfolio
    • Today's Newspaper (ePaper)
    • Crossword
    • Our Apps
    • Help Centre
    • Subscribe
    • Sign In